Trials / Recruiting
RecruitingNCT06598800
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug: BG-T187 | administered subcutaneously |
| DRUG | Other Therapeutic Agents | administered intravenously |
Timeline
- Start date
- 2024-10-18
- Primary completion
- 2028-09-30
- Completion
- 2028-09-30
- First posted
- 2024-09-19
- Last updated
- 2026-03-12
Locations
26 sites across 4 countries: United States, Australia, China, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06598800. Inclusion in this directory is not an endorsement.